Cadila Healthcare is currently trading at Rs. 396.10, up by 1.20 points or 0.30% from its previous closing of Rs. 394.90 on the BSE.
The scrip opened at Rs. 394.90 and has touched a high and low of Rs. 399.90 and Rs. 391.75 respectively. So far 34507 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 554.20 on 25-Jul-2017 and a 52 week low of Rs. 341.65 on 22-May-2018.
Last one week high and low of the scrip stood at Rs. 399.90 and Rs. 372.55 respectively. The current market cap of the company is Rs. 40529.97 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 16.64% and 8.40% respectively.
Zydus Cadila has signed a collaborative research agreement with the Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (IMTECH), Government of India. The research partnership will primarily aim to identify new drug candidates for treatment of drug-resistant infections.
The agreement between CSIR-IMTECH and the company will see scientists from both organizations working closely together on microbiology & genomics to identify new lead candidate as novel anti-tuberculosis compounds. For this project, scientists at IMTECH will utilize their expertise and scientific knowledge in microbiology, while
Zydus Cadila will provide its expertise in medicinal chemistry & pharmaceutical drug development with an aim to develop new drug combinations against drug-resistant pathogens which causes severe diseases in India and across the world.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1521.95 |
Dr. Reddys Lab | 6279.95 |
Cipla | 1407.55 |
Zydus Lifesciences | 963.50 |
Lupin | 1640.30 |
View more.. |